Matthew Atkins

Dr. Matthew Atkins

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
DTDavid Taylor
David Taylor
MAMatthew Atkins
Matthew Atkins
RHRobert Harland
Robert Harland
IBIrina Baburina
Irina Baburina
JMJames H MacCabe
James H MacCabe
PMPhilip McGuire
Philip McGuire
The use of clozapine demands regular monitoring of clozapine plasma concentrations and of white blood cell parameters. The delay between sending blood samples for analysis and receiving the results hinders clinical care. Point-of-care testing (POCT) can provide drug assay results within a few minutes. This study aimed to investigate the utility of a novel point-of-care device that can measure clozapine concentrations using capillary blood samples collected via a finger stick. During a five-week period starting in June 2019 eligible patients were asked to provide a finger-stick capillary sample in addition to their usual venous blood sample. Samples were analysed by the novel point-of-care device and by the standard laboratory method. Capillary blood samples were tested by the MyCare™ Insite POCT analyser, and a quantitative measurement of clozapine concentration was provided within six minutes. A total of 309 patients agreed to measurements by the two methods. Analysis revealed clozapine concentrations in venous blood as determined by the laboratory method ranged from 20 to 1310 ng/mL and by POCT from 7 to 1425 ng/mL. There was a strong positive correlation (R = 0.89) between the results from the venous and the capillary sample methods. The slope of the association between standard assay and MyCare™ Insite was 1.0 with an intercept of –21 ng/mL, indicating minimal bias. Clozapine concentrations can be accurately measured at the point of care using capillary blood samples collected via a finger stick. This approach may be more acceptable than venous sampling to patients and, with almost instant results available, more useful to clinicians.

22 November 2022 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
MAMatthew Atkins
Matthew Atkins
PMPhilip McGuire
Philip McGuire
BBBhirundra Balgobin
Bhirundra Balgobin
NDNeville Desouza
Neville Desouza
DTDavid Taylor
David Taylor

13 September 2022 in Psychiatry Research Communications
Verified
Journal Article
Open access
MAMatthew Atkins
Matthew Atkins
DTDavid Taylor
David Taylor
RHRobert Harland
Robert Harland
ABAaron Brewer
Aaron Brewer
SWSophie Williams
Sophie Williams
PMPhilip McGuire
Philip McGuire

1 January 2021 in Therapeutic Advances in Psychopharmacology
Verified
Journal Article
Open access
PDF file
MAMatthew Atkins
Matthew Atkins
PMPhilip McGuire
Philip McGuire
BBBhirundra Balgobin
Bhirundra Balgobin
PPPravinkumar Patel
Pravinkumar Patel
DTDavid Taylor
David Taylor
Background: Treatment with clozapine requires regular blood monitoring in order to minimise the risk of agranulocytosis. The demands on patients and clinicians associated with monitoring may be reduced by using point-of-care, as opposed to lab-based assessments. We assessed the utility of a device that can measure white blood cell (WBC) and neutrophil counts by capillary fingerstick blood. Method: The performance of a small, portable device (HemoCue® WBC DIFF System) was compared with that of a widely used laboratory analyser (ADVIA® 2120i) for measuring WBC and neutrophil counts. Patients with schizophrenia who were being treated with clozapine ( n = 201) provided a fingerstick capillary sample and a venous sample for the respective assays. Results: WBC counts and neutrophil counts from venous blood as determined by ADVIA 2120i, ranged from 3.0 × 109/l to 19.5 × 109/l, and 1.2 × 109/l to 15.9 × 109/l, respectively. There was a strong correlation between the results from venous and the capillary sample methods (WBC: R = 0.89, neutrophil: R = 0.92). By Passing–Bablok regression analysis, the slope of the association between ADVIA® 2120i and HemoCue WBC DIFF for WBC was 1.0 [95% confidence interval (CI) 0.944–1.086], with intercept at −0.9 (95% CI −1.43 to −0.45). For neutrophils, the slope was 0.870 (95% CI 0.817–0.923), with intercept at −0.19 (95% CI −0.43 to 0.02). Overall, mean biases of −0.95 × 109/l for WBC, and −0.91 × 109/l for neutrophils were observed for the capillary blood method compared with the venous blood method. Below the clinical cutoff intervals for clozapine monitoring WBC (<3.5 × 109/l) and neutrophils (<1.5 × 109/l) these biases were −1.1 × 109/l for WBC, and −0.25 × 109/l for neutrophils. Conclusion: Results from the capillary blood HemoCue WBC DIFF analyser compared well with the venous blood ADVIA 2120i analyser for determining WBC and neutrophil counts. There was a slight overall bias, with the capillary method reporting lower values for both measures. Fingerstick point-of-care analysis is suitable for monitoring blood counts in patients on clozapine, although confirmatory standard venous testing is recommended for test results falling below accepted thresholds.

25 May 2022 in Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
MAMatthew Atkins
Matthew Atkins
PMPhilip McGuire
Philip McGuire
BBBhirundra Balgobin
Bhirundra Balgobin
SWSophie Williams
Sophie Williams
FCFatou Ceesay
Fatou Ceesay
DTDavid Taylor
David Taylor
Objectives Patients treated with clozapine are required to have regular venous blood samples taken to measure white blood cell (WBC) and neutrophil counts to reduce the risk of agranulocytosis. The need for regular venous blood sampling can deter patients and clinicians from treatment with clozapine. Finger prick sampling offers patients a simpler and less invasive technique that is likely to be more acceptable. We undertook to evaluate a novel point of care testing (POCT) device which measures WBC and neutrophil counts using a small volume of capillary blood from a finger prick sample. Methods 215 patients who were being treated with clozapine and were having a venous blood sample taken for haematological monitoring also provided a fingerprick capillary blood sample. The capillary and venous samples were tested using the Sight OLO® POCT analyser, and the venous sample also tested using a standard laboratory method. Results For both the WBC and the neutrophil counts, there was a strong correlation between the results from the standard laboratory venous method and the POCT assay (R=0.94 and 0.95, respectively for capillary blood samples, and R=0.98 for both WBC and neutrophil counts for venous blood samples). Compared with the standard laboratory venous blood method, mean biases were −1.0×109/L for WBC and −0.5×109/L for neutrophils for the capillary blood POCT method, and −0.4×109/L for WBC and −0.4×109/L for neutrophils for the venous blood POCT method. Overall, 6 of 215 (2.8%) of patients had levels below clozapine monitoring thresholds (WBC <3.5×109/L and Neutrophils <1.5×109/L) by capillary blood, and 5 (2.3%) by venous blood by POCT. Of these, 2 had sub-threshold counts on the standard laboratory method. Conclusions The POCT analyser provided results for both WBC and neutrophil counts that were comparable with those from a standard venous blood laboratory method. Using POCT devices may make haematological monitoring easier in patients being treated with clozapine, and thereby increase the use of clozapine in the treatment of schizophrenia.

1 August 2025 in Methods and Protocols
Verified
Journal Article
Open access
PDF file
Gary McLeanGary McLean
Gary McLean
SSSamson Soyemi
Samson Soyemi
OAOluwafunmito P. Ajayi
Oluwafunmito P. Ajayi
SFSandra Fernando
Sandra Fernando
WSWiktor Sowinski-Mydlarz
Wiktor Sowinski-Mydlarz
DBDee Bhakta
Dee Bhakta
Vitamin D is the only vitamin that is conditionally essential, as it is synthesized from precursors after UV light exposure, whilst also being obtained from the diet. It has numerous health benefits, with deficiency becoming a major concern globally, such that dietary supplementation has more recently achieved vital importance to maintain satisfactory levels. In recent years, measurements made from blood have, therefore, become critical to determine the status of vitamin D levels in individuals and the larger population. Tests for vitamin D have routinely relied on laboratory analysis with sophisticated equipment, often being slow and costly, whilst rapid immunoassays have suffered from poor specificity and sensitivity. Here, we have evaluated a new rapid immunoassay test on the market (Rapi-D & IgLoo) to quickly and accurately measure vitamin D levels in small capillary blood specimens and compared this to measurements made using the standard laboratory method of liquid chromatography and mass spectrometry. Our results show that vitamin D can be measured very quickly and over a broad range using the new method, as well as correlate relatively well with standard laboratory testing; however, it cannot be fully relied upon currently to accurately diagnose deficiency or sufficiency in individuals. Our statistical and comparative analyses find that the rapid immunoassay with digital quantification significantly overestimates vitamin D levels, leading to diminished diagnosis of vitamin D deficiency. The speed and simplicity of the rapid method will likely provide advantages in various healthcare settings; however, further calibration of this rapid method and testing parameters for improving quantification of vitamin D from capillary blood specimens is required before integration of it into clinical decision-making pathways.